tiprankstipranks
Advertisement
Advertisement
Rapport Therapeutics files automatic mixed securities shelf
PremiumThe FlyRapport Therapeutics files automatic mixed securities shelf
1M ago
Rapport Therapeutics reports Q4 EPS (72c), consensus (67c)
Premium
The Fly
Rapport Therapeutics reports Q4 EPS (72c), consensus (67c)
1M ago
Rapport Therapeutics sees cash runway into 2H29
Premium
The Fly
Rapport Therapeutics sees cash runway into 2H29
1M ago
Rapport Therapeutics: Diversified Neurology Pipeline and Accelerated RAP-219 Development Underpin Buy Rating
PremiumRatingsRapport Therapeutics: Diversified Neurology Pipeline and Accelerated RAP-219 Development Underpin Buy Rating
3M ago
Premium
Ratings
Buy Rating on RAP-219 Underscored by Differentiated Clinical Profile, Conservative Phase 3 Design, and Favorable Risk–Reward
3M ago
Premium
Company Announcements
Rapport Therapeutics Establishes $110 Million At-The-Market Offering
3M ago
Rapport Therapeutics announces new data, post hox analysis on RAP-219
PremiumThe FlyRapport Therapeutics announces new data, post hox analysis on RAP-219
4M ago
Premium
Ratings
Buy Rating for Rapport Therapeutics: Promising Efficacy and Market Potential of RAP-219 in Epilepsy and Bipolar Mania
5M ago
Rapport Therapeutics initiated with a Buy at BTIG
Premium
The Fly
Rapport Therapeutics initiated with a Buy at BTIG
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100